# US 2023/0053846 A1 · Method for detecting cancer bone metastasis and detection reagent

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0053846 A1
- Document ID: US20230053846A1
- Status: Published application
- Kind: A1
- Application number: 17/778,593
- Filed: 2020-11-13
- Published: 2023-02-23
- Earliest claimed: 2019-11-22
- Assignees: Osaka University; Tosoh Corporation
- Applicants: Osaka University; Tosoh Corporation
- Inventors: Motohide UEMURA; Norio NONOMURA; Takeshi UJIKE; Shohei MYOBA; Norihisa OHTAKE
- Web page: https://patentgrep.com/patent/US20230053846A1

## CPC

- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- C07K 16/22: against growth factors {; against growth regulators}
- G01N 2333/495: Transforming growth factor [TGF]
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A problem to be addressed by the present invention is to provide: a method for detecting bone metastasis of cancer (excluding castration resistant prostate cancer) in a simple and highly accurate manner; and a reagent that can be used in the method. Bone metastasis of cancer (excluding castration resistant prostate cancer) is detected by measuring an intact growth and differentiation factor 15 (GDF15) propeptide level, a GDF15 propeptide fragment level, and the total of an intact GDF15 propeptide level and a GDF15 propeptide fragment level in a sample. The above described method for detecting bone metastasis of cancer includes a method for detecting bone metastasis of prostate cancer other than castration resistant prostate cancer, renal cancer, lung cancer, breast cancer, thyroid cancer, pancreatic cancer, bladder cancer, colon cancer, melanoma, myeloma, or lymphoma. Further, the reagent for detecting bone metastasis of cancer (excluding castration resistant prostate cancer) includes an antibody that specifically recognizes GDF15 propeptide.

## Claims

### Claim 1

A method for detecting bone metastasis of cancer (excluding castration resistant prostate cancer), the method comprising measuring an intact growth and differentiation factor 15 (GDF15) propeptide level in a sample.

### Claim 2

A method for detecting bone metastasis of cancer (excluding castration resistant prostate cancer), the method comprising measuring a GDF15 propeptide fragment level in a sample.

### Claim 3

A method for detecting bone metastasis of cancer (excluding castration resistant prostate cancer), the method comprising measuring a total of an intact GDF15 propeptide level and a GDF15 propeptide fragment level in a sample.

### Claim 4 (depends on 2)

The method according to claim 2, wherein the GDF15 propeptide fragment(s) comprise(s) the following GDF15 propeptide fragment(s) (A) and/or (B):
(A) a GDF15 propeptide fragment having the following properties:
contains an amino acid sequence from the lysine at the 58th residue to at least the aspartic acid at the 167th residue in the GDF15 amino acid sequence of SEQ ID NO:2, or a sequence having an identity of not less than 80% thereto; and
(B) a GDF15 propeptide fragment having the following properties:
contains an amino acid sequence from the glutamic acid at the 74th residue to at least the aspartic acid at the 167th residue in the GDF15 amino acid sequence of SEQ ID NO:2, or a sequence having an identity of not less than 80% thereto.

### Claim 5 (depends on 1)

The method according to any one of claims 1, wherein bone metastasis of prostate cancer other than castration resistant prostate cancer, renal cancer, lung cancer, breast cancer, thyroid cancer, pancreatic cancer, bladder cancer, colon cancer, melanoma, myeloma, or lymphoma is detected.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the measurement is carried out by an antigen-antibody reaction using an antibody that recognizes GDF15 propeptide.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the measurement is carried out using mass spectrometry.

### Claim 8

(canceled)

### Claim 9 (depends on 3)

The method according to claim 3, wherein the GDF15 propeptide fragment(s) comprise(s) the following GDF15 propeptide fragment(s) (A) and/or (B):
(A) a GDF15 propeptide fragment having the following properties:
contains an amino acid sequence from the lysine at the 58th residue to at least the aspartic acid at the 167th residue in the GDF15 amino acid sequence of SEQ ID NO:2, or a sequence having an identity of not less than 80% thereto; and
(B) a GDF15 propeptide fragment having the following properties:
contains an amino acid sequence from the glutamic acid at the 74th residue to at least the aspartic acid at the 167th residue in the GDF15 amino acid sequence of SEQ ID NO:2, or a sequence having an identity of not less than 80% thereto.

### Claim 10 (depends on 2)

The method according to claim 2, wherein bone metastasis of prostate cancer other than castration resistant prostate cancer, renal cancer, lung cancer, breast cancer, thyroid cancer, pancreatic cancer, bladder cancer, colon cancer, melanoma, myeloma, or lymphoma is detected.

### Claim 11 (depends on 3)

The method according to claim 3, wherein bone metastasis of prostate cancer other than castration resistant prostate cancer, renal cancer, lung cancer, breast cancer, thyroid cancer, pancreatic cancer, bladder cancer, colon cancer, melanoma, myeloma, or lymphoma is detected.

### Claim 12 (depends on 2)

The method according to claim 2, wherein the measurement is carried out by an antigen-antibody reaction using an antibody that recognizes GDF15 propeptide.

### Claim 13 (depends on 3)

The method according to claim 3, wherein the measurement is carried out by an antigen-antibody reaction using an antibody that recognizes GDF15 propeptide.

### Claim 14 (depends on 2)

The method according to claim 2, wherein the measurement is carried out using mass spectrometry.

### Claim 15 (depends on 3)

The method according to claim 3, wherein the measurement is carried out using mass spectrometry.
